Bernstein Harold sold $339K of MAZE
Bernstein Harold (President, R&D & CMO) sold 13,253 shares of Maze Therapeutics, Inc. (MAZE) at $25.57 ($0.34M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Provides a specific insider selling datapoint (13,253 shares at $25.5746) and confirms it was executed under a pre-arranged 10b5-1 plan, which generally reduces interpretive bearishness.
Market read
Traders may monitor MAZE for any filing-day sentiment/volume reaction, but the disclosure alone is unlikely to change fundamentals.
What to watch
The filing date can drive mechanical attention/short-term trading, even when the underlying sale occurred earlier (June 1).
Background
The filing is an SEC Form 4 insider transaction for Maze Therapeutics, reported via SEC EDGAR.
Ticker impact
SEC Form 4 shows MAZE R&D & CMO Harold Bernstein sold 13,253 shares in an open-market transaction under a 10b5-1 plan.
Likely limited, short-lived sentiment impact; watch for volume/price reaction around the filing date rather than a fundamental repricing.
The article provides a concrete sale datapoint (size, price, post-sale holdings) but no new company fundamentals or catalyst; 10b5-1 reduces interpretive weight.
Market effects
Minimal—this is company-specific insider transaction disclosure with no stated sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may reflect routine liquidity rather than negative expectations.
Key entities
- issuerMaze Therapeutics, Inc.
Subject of the SEC Form 4 insider transaction disclosure.
- insiderHarold Bernstein
President, R&D & CMO who sold shares under a 10b5-1 plan.
